GLP-1 Drugs Linked to 30% Higher Osteoporosis Risk
TL;DR Summary
A US observational study found that GLP-1 drugs (like Ozempic) may raise osteoporosis risk by about 30% (4% vs 3%) among people with obesity and type 2 diabetes, with osteomalacia also more common. Rapid weight loss and reduced intake of bone-building nutrients could contribute. The FDA already notes increased fracture risk in older adults and women; clinicians are urged to monitor bone health, nutrition and activity rather than discourage GLP-1 use.
- Drugs like Ozempic can increase your risk of a silent but serious health issue by 30% New York Post
- GLP-1s may increase risk of osteoporosis and gout, new research finds NBC News
- New risks issued for weight loss drugs amid recent research The Independent
- GLP-1 drugs like Ozempic and Wegovy may be linked to a slightly higher risk of these illnesses Audacy
- GLP-1 Use Associated with Lower Osteoporosis Risk in Adults with Type 2 Diabetes but Higher Risk in Adults Without Diabetes Epic Research
Reading Insights
Total Reads
1
Unique Readers
3
Time Saved
4 min
vs 5 min read
Condensed
92%
919 → 71 words
Want the full story? Read the original article
Read on New York Post